GRIA1 (Glutamate receptor 1) variants and mutations
GRIA1 (also known as Glutamate receptor 1) is a human protein-coding gene encoding a glutamate receptor 1 protein. An AMPA-type glutamate receptor subunit that forms a ligand-gated cation channel at excitatory synapses. Glutamate opens the receptor to convert a chemical signal into an electrical response, supporting fast transmission and activity-dependent plasticity in the brain. This analysis covers 1,369 GRIA1 variants and mutations. Of these, 83% have computational variant effect predictions. Disease context includes intellectual developmental disorder, autosomal dominant 67, epilepsy, and migraine disorder. Example GRIA1 variants include Q2Q, H3N, and H3H.
Variant analysis overview
- Gene: GRIA1
- Protein: Glutamate receptor 1
- UniProt accession: P42261
- Organism: Homo sapiens
- Variants analyzed: 1369
- Variant scope: all variants
- Completed: 2026-07-13
Variant and mutation evidence
- Variant composition: 1,205 unspecified-consequence records; 82 missense variants; 73 synonymous variants; 1 in-frame deletions; 2 stop-gained variants; 2 splice-region variants; 4 frameshift variants
- Prediction scores: 1,135 variants have prediction scores (83% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: intellectual developmental disorder, autosomal dominant 67, epilepsy, migraine disorder, alcohol dependence, Seizure, Lennox-Gastaut syndrome, obesity disorder, focal epilepsy, schizophrenia, diabetic neuropathy, type 2 diabetes mellitus, intellectual developmental disorder, autosomal recessive 76.
Protein structure and variant hotspots
- Protein features: 3 transmembrane segments; 6 binding sites; 10 post-translational modification sites.
- Structural context: 61 variants have structural context.
- PTM context: 13 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, PharmGKB, MaveDB, LitVar.
Notable GRIA1 variants
Examples include Q2Q, H3N, H3H, H3D, H3R, I4F, I4V, F5C. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- Q2Q (p.Gln2Gln), gnomAD 5-153492234-G-A, CADD 1.57
- H3N (p.His3Asn), gnomAD 5-153490895-C-A, REVEL 0.04, MetaLR 0.02
- H3H (p.His3His), rs1221074226, gnomAD 5-153490897-C-T, CADD 20.70
- H3D (p.His3Asp), gnomAD 5-153492214-C-G, CADD 0.01, SIFT 0.01
- H3R (p.His3Arg), rs1427171806, gnomAD 5-153492215-A-G, CADD 1.22, SIFT 0.03
- I4F (p.Ile4Phe), TOPMed rs1753850619, gnomAD rs1753850619, MetaLR 0.02, MetaSVM -1.05
- I4V (p.Ile4Val), TOPMed rs1753850619, gnomAD rs1753850619, REVEL 0.13, MetaLR 0.02
- F5C (p.Phe5Cys), NCI-TCGA Cosmic COSV9959, cosmic curated COSV99599, MetaLR 0.04, MetaSVM -1.12, Variant assessed as somatic; moderate impact.
- F5L (p.Phe5Leu), ExAC rs772311830, TOPMed rs772311830, gnomAD rs772311830, REVEL 0.09, MetaLR 0.02, Uncertain significance, not provided
- F5Y (p.Phe5Tyr), gnomAD 5-153490902-T-A, REVEL 0.16, MetaLR 0.03
- A6T (p.Ala6Thr), gnomAD rs1458884092, REVEL 0.08, MetaLR 0.02
- A6V (p.Ala6Val), gnomAD 5-153490905-C-T, REVEL 0.17, MetaLR 0.01
- F7S (p.Phe7Ser), gnomAD rs1232613217, REVEL 0.15, MetaLR 0.03
- F7V (p.Phe7Val), TOPMed rs1180322583, gnomAD rs1180322583, REVEL 0.05, MetaLR 0.02
- F7F (p.Phe7Phe), gnomAD 5-153490909-C-T, CADD 18.30
- F8L (p.Phe8Leu), NCI-TCGA Cosmic COSV5359, cosmic curated COSV53590, TOPMed rs1753852169, REVEL 0.09, MetaLR 0.01, Variant assessed as somatic; moderate impact.
- F8del (p.Phe8del), rs777672321, gnomAD 5-153490905-CCTT-, CADD 19.20
- F8F (p.Phe8Phe), rs1753852387, gnomAD 5-153490912-C-T, CADD 20.50
- C9* (p.Cys9Ter), gnomAD 5-153490915-C-A, CADD 20.20
- C9C (p.Cys9Cys), gnomAD 5-153490915-C-T, CADD 20.60
- C9R (p.Cys9Arg), gnomAD 5-153492205-T-C, CADD 15.30, SIFT 0.00
- C9S (p.Cys9Ser), gnomAD 5-153492206-G-C, CADD 11.80, SIFT 0.00
- C9F (p.Cys9Phe), rs539837953, gnomAD 5-153492275-G-T, CADD 23.60, SIFT 0.00
- T10A (p.Thr10Ala), gnomAD 5-153490916-A-G, REVEL 0.25, MetaLR 0.05
- T10T (p.Thr10Thr), rs775737542, gnomAD 5-153490918-C-T, CADD 19.90
- T10I (p.Thr10Ile), rs2113174948, gnomAD 5-153492284-C-T, CADD 21.40, SIFT 0.09
- G11C (p.Gly11Cys), cosmic curated COSV53588, REVEL 0.13, MetaLR 0.03
- G11S (p.Gly11Ser), TOPMed rs1418777145, gnomAD rs1418777145, REVEL 0.10, MetaLR 0.02
- L13L (p.Leu13Leu), rs1185887542, gnomAD 5-153490927-A-T, CADD 21.30
- L13F (p.Leu13Phe), gnomAD 5-153492217-C-T, CADD 9.35, SIFT 0.00
- L13S (p.Leu13Ser), rs888881381, gnomAD 5-153492227-C-CT, CADD 23.70
- L13P (p.Leu13Pro), rs3841128, gnomAD 5-153492228-T-TC, CADD 23.00
- G14D (p.Gly14Asp), NCI-TCGA Cosmic COSV9960, cosmic curated COSV99600, Variant assessed as somatic; moderate impact.
- G14R (p.Gly14Arg), TOPMed rs1753853461, MetaLR 0.10, MetaSVM -1.07
- G14G (p.Gly14Gly), rs768805842, gnomAD 5-153492243-C-T, CADD 2.30
- A15T (p.Ala15Thr), TOPMed rs921859652, gnomAD rs921859652, REVEL 0.03, MetaLR 0.02
- A15S (p.Ala15Ser), gnomAD 5-153490931-G-T, REVEL 0.04, MetaLR 0.02
- A15A (p.Ala15Ala), rs760854220, gnomAD 5-153490933-G-T, CADD 18.90
- A15P (p.Ala15Pro), rs542321362, gnomAD 5-153492238-G-C, CADD 16.40, SIFT 0.16
- A15V (p.Ala15Val), gnomAD 5-153492239-C-T, CADD 13.60, SIFT 1.00
- V16V (p.Val16Val), rs1168502713, gnomAD 5-153490936-A-C, CADD 19.90
- V17A (p.Val17Ala), rs369322935, cosmic curated COSV53620, ESP rs369322935, ExAC rs369322935, REVEL 0.10, MetaLR 0.02, Variant assessed as somatic; moderate impact.
- V17G (p.Val17Gly), ESP rs369322935, ExAC rs369322935, TOPMed rs369322935, gnomAD rs369322935, REVEL 0.15, MetaLR 0.02
- V17L (p.Val17Leu), Ensembl rs1029712267, REVEL 0.04, MetaLR 0.01
- V17V (p.Val17Val), rs774208197, gnomAD 5-153492291-T-C, CADD 13.80
- V17M (p.Val17Met), rs1384295369, gnomAD 5-153492307-G-A, CADD 18.40, SIFT 0.00
- V17E (p.Val17Glu), rs1561581220, gnomAD 5-153492308-T-A, CADD 22.40, SIFT 0.00
- G18D (p.Gly18Asp), ExAC rs776558930, gnomAD rs776558930, REVEL 0.33, MetaLR 0.08
- G18S (p.Gly18Ser), gnomAD rs1411545506, REVEL 0.18, MetaLR 0.07
- G18R (p.Gly18Arg), gnomAD 5-153490940-G-C, REVEL 0.28, MetaLR 0.08
- A19V (p.Ala19Val), gnomAD rs1335140610, REVEL 0.07, MetaLR 0.02
- A19T (p.Ala19Thr), gnomAD 5-153490943-G-A, REVEL 0.03, MetaLR 0.02
- N20H (p.Asn20His), gnomAD 5-153490946-A-C, REVEL 0.16, MetaLR 0.05
- N20S (p.Asn20Ser), gnomAD 5-153490947-A-G, REVEL 0.09, MetaLR 0.02
- P22A (p.Pro22Ala), Ensembl rs145860630
- P22H (p.Pro22His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P22S (p.Pro22Ser), cosmic curated COSV53613, MetaLR 0.13, MetaSVM -0.95
- P22P (p.Pro22Pro), gnomAD 5-153490954-C-T, CADD 19.60
- P22L (p.Pro22Leu), gnomAD 5-153492227-C-T, CADD 18.00, SIFT 0.08
- N23K (p.Asn23Lys), NCI-TCGA TCGA novel, MetaLR 0.03, MetaSVM -1.09, Variant assessed as somatic; moderate impact.
- N23S (p.Asn23Ser), gnomAD rs1380045490, REVEL 0.06, MetaLR 0.02
- N23N (p.Asn23Asn), gnomAD 5-153490957-C-T, CADD 19.60
- N24H (p.Asn24His), TOPMed rs1244792378, gnomAD rs1244792378, REVEL 0.04, MetaLR 0.04
- N24Y (p.Asn24Tyr), gnomAD 5-153490958-A-T, REVEL 0.18, MetaLR 0.06
- N24N (p.Asn24Asn), gnomAD 5-153490960-T-C, CADD 19.00
- I25I (p.Ile25Ile), rs148776379, gnomAD 5-153490963-C-A, CADD 19.90
- Q26H (p.Gln26His), cosmic curated COSV99602, MetaLR 0.05, MetaSVM -1.12
- I27I (p.Ile27Ile), rs150205263, gnomAD 5-153490969-C-A, CADD 19.20
- G28=, rs1045297658, NCI-TCGA Cosmic COSV5361, Variant assessed as somatic; low impact.
- G28W (p.Gly28Trp), Ensembl rs201847050, MetaLR 0.14, MetaSVM -0.98
- G28R (p.Gly28Arg), gnomAD 5-153490970-G-A, REVEL 0.62, MetaLR 0.21
- G29A (p.Gly29Ala), cosmic curated COSV53620, TOPMed rs1754169954, REVEL 0.26, MetaLR 0.39
- G29E (p.Gly29Glu), NCI-TCGA Cosmic COSV5362, cosmic curated COSV53622, NCI-TCGA Cosmic COSV9960, Variant assessed as somatic; moderate impact.
- G29V (p.Gly29Val), NCI-TCGA Cosmic COSV5362, NCI-TCGA Cosmic COSV9960, cosmic curated COSV99600, MetaLR 0.40, MetaSVM -0.22, Variant assessed as somatic; moderate impact.
- G29G (p.Gly29Gly), rs1754170362, gnomAD 5-153493932-A-G, CADD 13.70
- L30V (p.Leu30Val), NCI-TCGA Cosmic COSV9960, cosmic curated COSV99600, MetaLR 0.18, MetaSVM -0.82, Variant assessed as somatic; moderate impact.
- L30F (p.Leu30Phe), gnomAD 5-153492267-CTTGC, CADD 25.80
- L30L (p.Leu30Leu), gnomAD 5-153492268-T-C, CADD 14.40
- L30W (p.Leu30Trp), rs1204803494, gnomAD 5-153492269-T-G, CADD 27.20, SIFT 0.01
- L30I (p.Leu30Ile), gnomAD 5-153492295-C-A, CADD 16.40, SIFT 0.43
- L30P (p.Leu30Pro), rs759519627, gnomAD 5-153492296-T-C, CADD 17.10, SIFT 0.23
- L30* (p.Leu30Ter), gnomAD 5-153493934-T-A, CADD 36.00
- F31L (p.Phe31Leu), gnomAD rs1754170993, REVEL 0.33, MetaLR 0.22
- F31F (p.Phe31Phe), rs959841194, gnomAD 5-153492279-C-T, CADD 12.30
- P32Q (p.Pro32Gln), cosmic curated COSV99598
- P32R (p.Pro32Arg), ExAC rs760507454, TOPMed rs760507454, gnomAD rs760507454, REVEL 0.33, MetaLR 0.13
- P32S (p.Pro32Ser), cosmic curated COSV53594, MetaLR 0.13, MetaSVM -0.98, Uncertain significance, not provided
- P32L (p.Pro32Leu), rs191642595, gnomAD 5-153492302-C-T, CADD 18.20, SIFT 0.20
- P32P (p.Pro32Pro), rs763830390, gnomAD 5-153493941-A-G, CADD 9.54
- N33Y (p.Asn33Tyr), TOPMed rs1421139721, gnomAD rs1421139721, REVEL 0.25, MetaLR 0.06
- N33K (p.Asn33Lys), gnomAD 5-153493944-C-A, REVEL 0.07, MetaLR 0.05
- Q34K (p.Gln34Lys), cosmic curated COSV99599
- Q34L (p.Gln34Leu), ExAC rs753472750, gnomAD rs753472750, MetaLR 0.05, MetaSVM -1.03
- Q34Q (p.Gln34Gln), gnomAD 5-153493947-G-A, CADD 8.93
- S36V (p.Ser36Val), gnomAD 5-153492207-CA-C, CADD 12.30
- S36C (p.Ser36Cys), rs977836903, gnomAD 5-153492262-A-T, CADD 22.80, SIFT 0.03
- S36G (p.Ser36Gly), gnomAD 5-153492262-A-G, CADD 22.20, SIFT 0.17
- S36T (p.Ser36Thr), rs1348726270, gnomAD 5-153492263-G-C, CADD 13.90, SIFT 0.79
- S36N (p.Ser36Asn), gnomAD 5-153492263-G-A, CADD 16.00, SIFT 0.23
- Q37H (p.Gln37His), NCI-TCGA Cosmic COSV9959, cosmic curated COSV99597, Variant assessed as somatic; moderate impact.
- Q37L (p.Gln37Leu), cosmic curated COSV10725, MetaLR 0.07, MetaSVM -1.10
- Q37R (p.Gln37Arg), gnomAD 5-153493955-A-G, REVEL 0.26, MetaLR 0.07
- Q37Q (p.Gln37Gln), rs747584809, gnomAD 5-153493956-G-A, CADD 9.33
- E38D (p.Glu38Asp), ESP rs369571702, ExAC rs369571702, TOPMed rs369571702, gnomAD rs369571702, REVEL 0.26, MetaLR 0.13
- E38Q (p.Glu38Gln), ExAC rs761521056, gnomAD rs761521056, REVEL 0.21, MetaLR 0.14
- E38V (p.Glu38Val), rs1224873266, gnomAD 5-153492251-A-T, CADD 6.98, SIFT 1.00
- E38G (p.Glu38Gly), gnomAD 5-153493958-A-G, REVEL 0.35, MetaLR 0.15
- H39D (p.His39Asp), ExAC rs749875254, TOPMed rs749875254, gnomAD rs749875254, REVEL 0.46, MetaLR 0.50
- H39R (p.His39Arg), NCI-TCGA Cosmic COSV5358, cosmic curated COSV53587, MetaLR 0.48, MetaSVM 0.07, Variant assessed as somatic; moderate impact.
- H39Y (p.His39Tyr), ExAC rs749875254, TOPMed rs749875254, gnomAD rs749875254, REVEL 0.26, MetaLR 0.35
- H39H (p.His39His), gnomAD 5-153493962-T-C, CADD 11.40
- A40G (p.Ala40Gly), cosmic curated COSV53629
- A40S (p.Ala40Ser), cosmic curated COSV53626, MetaLR 0.41, MetaSVM -0.36
- A41T (p.Ala41Thr), ESP rs146859383, TOPMed rs146859383, gnomAD rs146859383, REVEL 0.66, MetaLR 0.79, Uncertain significance, not specified
- A41A (p.Ala41Ala), gnomAD 5-153493968-T-C, CADD 12.60
- F42L (p.Phe42Leu), cosmic curated COSV53608, MetaLR 0.68, MetaSVM 0.48
- F42F (p.Phe42Phe), rs962984422, gnomAD 5-153493971-T-C, CADD 13.70
- R43K (p.Arg43Lys), Ensembl rs905047201, Uncertain significance, Intellectual developmental disorder, autosomal dominant 67
- R43R (p.Arg43Arg), gnomAD 5-153493974-A-G, CADD 14.20
- R43S (p.Arg43Ser), gnomAD 5-153493974-A-T, REVEL 0.70, MetaLR 0.53
- F44L (p.Phe44Leu), ESP rs140887009, ExAC rs140887009, gnomAD rs140887009, REVEL 0.37, MetaLR 0.57
- F44F (p.Phe44Phe), rs939083658, gnomAD 5-153493977-T-C, CADD 11.50
- A45P (p.Ala45Pro), NCI-TCGA Cosmic COSV5359, cosmic curated COSV53594, NCI-TCGA Cosmic COSV9959, Variant assessed as somatic; moderate impact.
- A45T (p.Ala45Thr), cosmic curated COSV99599, Ensembl rs147434856, MetaLR 0.88, MetaSVM 0.94
- L46F (p.Leu46Phe), cosmic curated COSV53596
- S47L (p.Ser47Leu), rs780495356, ClinGen CA3524233, cosmic curated COSV53607, ClinVar RCV002673675, REVEL 0.25, MetaLR 0.09, Uncertain significance, Inborn genetic diseases
- S47T (p.Ser47Thr), Ensembl rs771472631, REVEL 0.16, MetaLR 0.09
- S47S (p.Ser47Ser), rs751940097, gnomAD 5-153493986-G-C, CADD 9.33
- Q48Q (p.Gln48Gln), rs1754177388, gnomAD 5-153493989-A-G, CADD 11.80
- L49F (p.Leu49Phe), Ensembl rs1754177699, REVEL 0.16, MetaLR 0.38
- L49R (p.Leu49Arg), gnomAD 5-153493991-T-G, REVEL 0.28, MetaLR 0.54
- L49L (p.Leu49Leu), gnomAD 5-153493992-C-T, CADD 11.90
- T50A (p.Thr50Ala), gnomAD rs1408793480, REVEL 0.31, MetaLR 0.29
- T50T (p.Thr50Thr), rs1450978833, gnomAD 5-153493995-A-G, CADD 11.50
- E51E (p.Glu51Glu), gnomAD 5-153493998-G-A, CADD 10.40
- P52S (p.Pro52Ser), gnomAD 5-153493999-C-T, REVEL 0.20, MetaLR 0.48
- P52L (p.Pro52Leu), gnomAD 5-153494000-C-T, REVEL 0.27, MetaLR 0.60
- P52P (p.Pro52Pro), rs1754178569, gnomAD 5-153494001-C-T, CADD 12.90
- P53L (p.Pro53Leu), NCI-TCGA Cosmic COSV5361, REVEL 0.22, MetaLR 0.14, Uncertain significance, Inborn genetic diseases
- P53R (p.Pro53Arg), gnomAD rs1754178854, REVEL 0.31, MetaLR 0.08, Uncertain significance, Inborn genetic diseases
- P53S (p.Pro53Ser), rs2532320830, ClinGen CA362001453, ClinVar RCV003153198, Uncertain significance, Intellectual developmental disorder, autosomal dominant 67
- P53P (p.Pro53Pro), rs755342972, gnomAD 5-153494004-G-A, CADD 7.47
- K54* (p.Lys54Ter), cosmic curated COSV53606
- K54E (p.Lys54Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- K54M (p.Lys54Met), Ensembl rs1561582892, MetaLR 0.61, MetaSVM 0.25
- K54N (p.Lys54Asn), ExAC rs781593854, gnomAD rs781593854, REVEL 0.26, MetaLR 0.49, Uncertain significance, Inborn genetic diseases
- L56F (p.Leu56Phe), gnomAD 5-153494011-C-T, REVEL 0.26, MetaLR 0.52
- P57H (p.Pro57His), gnomAD 5-153494015-C-A, REVEL 0.61, MetaLR 0.71
- Q58* (p.Gln58Ter), cosmic curated COSV10513
- Q58E (p.Gln58Glu), TOPMed rs960833805, gnomAD rs960833805, REVEL 0.23, MetaLR 0.08
- Q58H (p.Gln58His), NCI-TCGA Cosmic COSV5361, cosmic curated COSV53615, Variant assessed as somatic; moderate impact.
- Q58K (p.Gln58Lys), TOPMed rs960833805, gnomAD rs960833805, REVEL 0.27, MetaLR 0.09
- Q58L (p.Gln58Leu), cosmic curated COSV53623, MetaLR 0.08, MetaSVM -1.10
- I59F (p.Ile59Phe), Ensembl rs1561582921, REVEL 0.56, MetaLR 0.56
- I59M (p.Ile59Met), Ensembl rs2113189726
- I59V (p.Ile59Val), Ensembl rs1561582921, MetaLR 0.31, MetaSVM -0.48
- I59T (p.Ile59Thr), gnomAD 5-153494021-T-C, REVEL 0.57, MetaLR 0.56
- D60D (p.Asp60Asp), rs748389572, gnomAD 5-153494025-T-C, CADD 12.80
- I61T (p.Ile61Thr), NCI-TCGA TCGA novel, REVEL 0.46, MetaLR 0.50, Variant assessed as somatic; moderate impact.
- I61I (p.Ile61Ile), rs756349055, gnomAD 5-153494028-T-C, CADD 13.40
- V62A (p.Val62Ala), cosmic curated COSV53597, REVEL 0.60, MetaLR 0.61
- N63S (p.Asn63Ser), NCI-TCGA TCGA novel, MetaLR 0.36, MetaSVM -0.53, Variant assessed as somatic; moderate impact.
- N63N (p.Asn63Asn), rs1217969979, gnomAD 5-153494034-C-T, CADD 11.70
- I64T (p.Ile64Thr), NCI-TCGA Cosmic COSV5362, cosmic curated COSV53624, Variant assessed as somatic; moderate impact.
- I64V (p.Ile64Val), cosmic curated COSV10807, MetaLR 0.40, MetaSVM -0.41
- S65G (p.Ser65Gly), TOPMed rs1455172439, gnomAD rs1455172439, REVEL 0.28, MetaLR 0.26
- S65R (p.Ser65Arg), ExAC rs778014621, TOPMed rs778014621, gnomAD rs778014621, REVEL 0.46, MetaLR 0.37
- S65S (p.Ser65Ser), rs778014621, gnomAD 5-153494040-C-T, CADD 4.46
- D66N (p.Asp66Asn), rs144700432, ClinGen CA3524241, cosmic curated COSV10878, ClinVar RCV004393714, REVEL 0.12, MetaLR 0.28, Uncertain significance, Inborn genetic diseases
- S67R (p.Ser67Arg), cosmic curated COSV53606, MetaLR 0.27, MetaSVM -0.54
- S67I (p.Ser67Ile), gnomAD 5-153494045-G-T, REVEL 0.41, MetaLR 0.29
- S67S (p.Ser67Ser), rs1561582982, gnomAD 5-153494046-C-T, CADD 11.80
- F68L (p.Phe68Leu), gnomAD 5-153494049-T-G, REVEL 0.62, MetaLR 0.54
- E69D (p.Glu69Asp), Ensembl rs923401532, MetaLR 0.32, MetaSVM -0.48
- E69G (p.Glu69Gly), Ensembl rs1405946594, REVEL 0.34, MetaLR 0.38
- E69Q (p.Glu69Gln), Ensembl rs1754183528, REVEL 0.29, MetaLR 0.35
- M70I (p.Met70Ile), rs2532321312, ClinVar RCV004560528, Uncertain significance, Intellectual developmental disorder, autosomal dominant 67
- M70T (p.Met70Thr), Ensembl rs867068859, MetaLR 0.05, MetaSVM -1.09
- T71A (p.Thr71Ala), NCI-TCGA Cosmic COSV5361, cosmic curated COSV53616, MetaLR 0.07, MetaSVM -1.09, Variant assessed as somatic; moderate impact.
- Y72Y (p.Tyr72Tyr), rs775520279, gnomAD 5-153494061-T-C, CADD 10.00
Public GRIA1 analysis runs
- GRIA1 analysis run — GRIA1 (1,369 variants) — completed 2026-07-13
- GRIA1 analysis run — GRIA1 (1,369 variants) — completed 2026-07-13